Get to Know the People and the Unique Approach That Make Altasciences a Different Kind of CRO/CDMO
 Manufacturing and Handling Your Highly Potent APIs and Controlled Substances Ben Reed, General Manager of CDMO Services, describes how Altasciences has the equipment and expertise for your highly potent API projects. Watch the video » |
 The Makings of a CNS Center of Excellence Dr. Denise Milovan, Senior Neuroscientist and Neuropsychologist, shares her work experience and insight on what makes Altasciences a CNS Center of Excellence. Watch the video » |
||||
 Complex and Customized Formulation Development Andrew Buis, Senior Formulation Scientist, explains how Altasciences is equipped to formulate your highly potent APIs and controlled substances. Watch the video » |
 Expertise in Preclinical Toxicology Studies Dr. Norbert Makori, Vice President, Toxicology, succinctly details how Altasciences helps you evaluate the safety of your therapeutic candidates. Watch the video » |
||||
 Experts in Complex Clinical Trials Dr. Gaetano Morelli, Chief Medical Officer, shares his insight and first-hand experience in how Altasciences conducts your complex clinical trials. Watch the video » |
 Bioanalytical Operational Excellence Frédéric Massé, Senior Director, Bioanalytical Operations, and Mathieu Saulnier, Senior Director, Technical Support, provide an inside look to how our bioanalytical teams work. Watch the video » |
||||
|
|
||||
| Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond. | |||||
A Virtual Tour You Won't Want to Miss!
A Virtual Tour You Won't Want to Miss!
Step inside our nonclinical facility in Scranton, PA, with this virtual tour. Discover how our expertise in efficacy pharmacology, ophthalmology, and carcinogenicity, to name a few, can support your nonclinical study needs.
Highlights include:
- 40 animal rooms
- Capacity to house ~140 NHPs, ~350 canines, ~350 swine, and ~6,500 rodents
- On-site archive facility (1,840 sq. ft.)
- Accreditations/Certifications:
- AAALAC accredited
- USDA registered
- EPA inspected
REQUEST A TOUR NOW
Speak with one of our experts to learn more about our service offering.
Have five minutes? Take a look at these:
Webpages: Preclinical Testing Facilities
Fact Sheet: Preclinical Drug Development
Webinar: Navigating the Challenges of Early Drug Development
Altasciences Selects Proscia to Safely Accelerate the Discovery and Development of Life-Saving Drugs
Proscia®, a leading provider of digital and computational pathology solutions, announced that Altasciences has chosen Concentriq® for Research to help sponsors get life-saving therapeutics to patients sooner.
You may also be interested in:
- Our Proactive Drug Development Solution
- eBook: Nonclinical Safety Testing Guide
- The Altascientist: Planning Your Preclinical Assessment
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Get Ahead of the Game with Flexible Phase 1 Study Timing
Overcoming Nonclinical and Clinical Immunogenicity Assessment Challenges
Are you facing challenges in validating immunogenicity assays required for your drug development program?
In this edition of The Altascientist, learn about the different purposes and challenges of validating immunogenicity assays to strategically develop a safe and quick approach to support nonclinical and clinical studies.
Have questions? Consult with one of our experts.
You may also be interested in these scientific posters presented at the 15th WRIB (Workshops on Recent Issues in Bioanalysis):
- Dual Purpose of a Cell-Based Assay for an Agonist of the GLP-2 Receptor
- Development of an Oligonucleotide Drug Immunogenicity Assay: A Case for the Characterization of the Immune Response
- Development of an Oligonucleotide Drug Immunogenicity Assay: A Case for the Characterization of the Immune Response Using an Anti-Drug-Antibody Screening Assay to Resolve Selectivity Issues in Toxicokinetic Ligand-Binding Assays
Altasciences is at the forefront of microsampling, leveraging innovative technology that allows for significantly reduced blood volumes to be taken from study participants. Our fully customizable bioanalytical solutions are available as stand-alone or as part of a complete drug development program.